We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$24.5B
$665M 6.75%
1,727,349
-814,951
-32% -$301M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$123B
$320M 3.24%
1,761,616
+27,922
+2% +$5.45M
IONS icon
3
Ionis Pharmaceuticals
IONS
$8.99B
$314M 3.18%
9,347,926
-582,319
-6% -$21.9M
ARGX icon
4
argenx
ARGX
$53.8B
$297M 3.02%
983,938
+9,900
+1% +$3.14M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$288M 2.92%
3,004,051
-13,700
-0.5% -$1.29M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$35.7B
$266M 2.7%
1,408,418
-140,674
-9% -$26.4M
INCY icon
7
Incyte
INCY
$23.4B
$203M 2.06%
2,957,000
-14,400
-0.5% -$1.09M
ISRG icon
8
Intuitive Surgical
ISRG
$122B
$202M 2.05%
610,785
+4,500
+0.7% +$1.51M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.36B
$200M 2.03%
4,341,992
-11,000
-0.3% -$531K
FATE icon
10
Fate Therapeutics
FATE
$324M
$192M 1.95%
3,238,036
+624,500
+24% +$49M
ARVN icon
11
Arvinas
ARVN
$517M
$184M 1.87%
2,241,403
+4,000
+0.2% +$354K
MGNX icon
12
MacroGenics
MGNX
$285M
$179M 1.82%
8,544,597
+1,168,571
+16% +$28.1M
ELV icon
13
Elevance Health
ELV
$80.9B
$177M 1.8%
475,210
+9,234
+2% +$3.51M
ABT icon
14
Abbott
ABT
$175B
$164M 1.66%
1,387,499
+10,000
+0.7% +$1.23M
BIIB icon
15
Biogen
BIIB
$30.4B
$149M 1.51%
527,000
-1,100
-0.2% -$361K
DXCM icon
16
DexCom
DXCM
$29.6B
$144M 1.46%
1,055,356
+76,252
+8% +$9.62M
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$142M 1.44%
3,209,004
+844,800
+36% +$38.7M
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$141M 1.43%
3,773,919
+164,000
+5% +$5.7M
DHR icon
19
Danaher
DHR
$144B
$139M 1.41%
515,134
-29,622
-5% -$8.06M
UNH icon
20
UnitedHealth
UNH
$387B
$132M 1.34%
337,982
-5,069
-1% -$2.1M
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
$129M 1.31%
5,769,039
+500,000
+9% +$11M
BSX icon
22
Boston Scientific
BSX
$65.4B
$129M 1.31%
2,967,127
+640,340
+28% +$28.3M
TNDM icon
23
Tandem Diabetes Care
TNDM
$1.17B
$124M 1.25%
1,034,519
+14,151
+1% +$1.56M
HUM icon
24
Humana
HUM
$48B
$122M 1.24%
312,762
+30,007
+11% +$12.7M
RLAY icon
25
Relay Therapeutics
RLAY
$4.34B
$118M 1.2%
3,755,962
+1,115,000
+42% +$37.5M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.